Exxel Pharma is focused on

  • Commercialization of its two drugs, URB597 and URB937, and providing innovative medicines to current, unmet medical needs.
  • Positioning URB937 as a safe, non-addictive alternative to opioid drugs for pain management.
  • Expanding the Company’s drug pipeline with follow-on molecules, and maximizing the value of the Company’s IP portfolio.
  • Achieving the goal of providing optimal returns for our investors.

Video Presentation

Corporate Presentation